Cougar Biotechnology, Inc.
Home | Careers | Contact | Site Map
Cougar Biotechnology, Inc.CompanyNewsResearch and DevelopmentInvestor Relations
PipelineCB7630CB3304CB1089Noscapine Analogs
Research and Development

Cougar Biotechnology, Inc. is a Los Angeles-based company with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase III clinical trial in prostate cancer and a Phase I/II trial in breast cancer; CB3304, which is currently in a Phase I trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types.

On July 10, 2009, Johnson & Johnson acquired Cougar. Click here for a link to the press release announcing the acquisition.

Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax